JTCS Click here to go to SJM website.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
Gilbert H.L. Tang
Shafie Fazel
Richard D. Weisel
Subodh Verma
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tang, G. H.L.
Right arrow Articles by Li, R.-K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tang, G. H.L.
Right arrow Articles by Li, R.-K.
Related Collections
Right arrowRelated Article

J Thorac Cardiovasc Surg 2005;130:966-968
© 2005 The American Association for Thoracic Surgery

Editorial

Optimizing cardiac cell therapy: From processing to delivery

Gilbert H.L. Tang, MD, Shafie Fazel, MD, MSc, Richard D. Weisel, MD, Subodh Verma, MD, PhD, Ren-Ke Li, MD, PhD *

Division of Cardiovascular Surgery, Toronto General Hospital, University of Toronto, Toronto, Ontario, Canada

Received for publication April 4, 2005; revisions received April 25, 2005; accepted for publication May 3, 2005.

* Address for reprints: Ren-Ke Li, MD, PhD, Toronto General Hospital, NU 1-115A, 200 Elizabeth St, Toronto, Ontario, Canada M5G 2C4 (Email: RenKeLi@uhnres.utoronto.ca).

The first 20% of the full text of this article appears below.

In this issue, McConnell and colleagues 1 Go report a detailed examination of the impact of autologous skeletal myoblast transplantation in a chronic ischemic cardiomyopathy model in sheep. They injected the cells prepared by GenVec, Inc, at multiple sites in the infarct zone. They concluded that cardiac contractility was not improved, but cell implantation prevented ventricular dilation. The study highlights several important issues in cardiac cell therapy and its future in clinical application.

Most preclinical reports have demonstrated improvement in systolic and diastolic properties after cell transplantation. 2 Go According to McConnell and colleagues, 1 Go however, the predominant impact of myoblast implantation was not on systolic function. Their finding could be related to the data analysis. For example, a significant enhancement of cardiac performance might have been detected if they had made pressure and volume measurements at lower volumes and if they had performed a more robust statistical analysis (an analysis of covariance).

In this study, McConnell and colleagues 1 Go reported at 6 weeks a 21% reduction in end-systolic volume index (ESVI) in cell-transplanted . . . [Full Text of this Article]


Related Article

Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure
Patrick I. McConnell, Carlos L. del Rio, Douglas B. Jacoby, Martina Pavlicova, Pawel Kwiatkowski, Agatha Zawadzka, Jonathan H. Dinsmore, Louis Astra, Sheik Wisel, and Robert E. Michler
J. Thorac. Cardiovasc. Surg. 2005 130: 1001. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 J. Thorac. Cardiovasc. Surg.Home page
H. Gulbins
Correlation of autologous skeletal myoblast survival with changes in left ventricular remodeling in dilated ischemic heart failure
J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1422 - 1422.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The American Association for Thoracic Surgery.